Protein carbamylation predicts mortality in ESRD

Journal of the American Society of Nephrology

Volumn 24, Issue 5, 2013, Pages 853-861

  Koeth, Robert A ^a   Kalantar Zadeh, Kamyar ^b,c   Wang, Zeneng ^a   Fu, Xiaoming ^a   Tang, W H Wilson ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HOMOCITRULLINE; HOMOCYSTEINE; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; PROTEIN BOUND HOMOCITRULLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARBAMOYLATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CARBAMOYLATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UREMIA;

EID: 84877087172     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012030254     Document Type: Article

References (58)

1. Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325: 163-167, 2003
2. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9[Suppl]: S16-S23, 1998
3. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606-1615, 1999 (Pubitemid 29297538)
4. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 11: 239-245, 1998 (Pubitemid 28511522)
5. Wright J, Hutchison A: Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag 5: 713-722, 2009
6. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000 (Pubitemid 30438520)
7. Hörkkö S, Huttunen K, Kervinen K, Kesäniemi YA: Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 24: 105-113, 1994
8. Kraus LM, Elberger AJ, Handorf CR, Pabst MJ, Kraus AP Jr: Urea-derived cyanate forms epsilon-amino-carbamoyl-lysine (homocitrulline) in leukocyte proteins in patients with end-stage renal disease on peritoneal dialysis. J Lab Clin Med 123: 882-891, 1994
9. Mun KC, Kim HC, Kwak CS: Cyanate as a hemolytic factor. Ren Fail 22: 809-814, 2000
10. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV: Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease. Kidney Int 68: 173-178, 2005 (Pubitemid 43181374)
11. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49: 1428-1434, 1996 (Pubitemid 26166417)
12. Stim J, Shaykh M, Anwar F, Ansari A, Arruda JA, Dunea G: Factors determining hemoglobin carbamylation in renal failure. Kidney Int 48: 1605-1610, 1995
13. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13: 1176-1184, 2007 (Pubitemid 47530630)
14. Stark G, Stein WH, Moore S: Reactions of the cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 235: 3177-3181, 1960
15. Kraus LM, Kraus AP Jr: Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 78: S102-S107, 2001 (Pubitemid 32144080)
16. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158: 879-891, 2001 (Pubitemid 32221781)
17. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003 (Pubitemid 37337595)
18. Depner TA: Uremic toxicity: Urea and beyond. Semin Dial 14: 246-251, 2001
19. Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, Shishido K, Akizawa T: Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 220: 493-501, 2012
20. Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B: Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. Clin Chim Acta 411: 2079-2082, 2010
21. Scialla JJ, Plantinga LC, Kao WH, Jaar B, Powe NR, Parekh RS: Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients. Am J Nephrol 33: 224-230, 2011
22. Kovesdy CP, Kalantar-Zadeh K: Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 14: 408-415, 2009
23. Verduijn M, Maréchal C, Coester AM, Sampimon DE, Boeschoten EW, Dekker FW, Goffin E, Krediet RT, Devuyst O: The -174G/C variant of IL6 as risk factor for mortality and technique failure in a large cohort of peritoneal dialysis patients. Nephrol Dial Transplant 27: 3516-3523, 2012
24. Verduijn M, Prein RA, Stenvinkel P, Carrero JJ, le Cessie S, Witasp A, Nordfors L, Krediet RT, Boeschoten EW, Dekker FW: Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. Nephrol Dial Transplant 26: 239-245, 2011
25. Amabile N, Guérin AP, Tedgui A, Boulanger CM, London GM: Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: A pilot study. Nephrol Dial Transplant 27: 1873-1880, 2012
26. Chen KH, Lin JL, Lin-Tan DT, Hsu CW, Huang WH, Yen TH, Weng SM, Hung CC: Glycated hemoglobin predicts mortality in nondiabetic patients receiving chronic peritoneal dialysis. Am J Nephrol 32: 567-574, 2010
27. Sebeková K, Klenovicsová K, Ferenczová J, Hedvig J, Podracká L, Heidland A: Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency. J Ren Nutr 22: 143-148, 2012
28. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
29. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63: 793-808, 2003 (Pubitemid 36315558)
30. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004 (Pubitemid 38129749)
31. Mun KC, Golper TA: Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 18: 13-17, 2000
32. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54: 561-569, 1998 (Pubitemid 28357420)
33. Horinek A, Misra M: Does residual renal function decline more rapidly in hemodialysis than in peritoneal dialysis? How good is the evidence? Adv Perit Dial 20: 137-140, 2004
34. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG: Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 21: 1852-1857, 2010
35. Bobb D, Hofstee BH: Gel isoelectric focusing for following the successive carbamylations of amino groups in chymotrypsinogen A. Anal Biochem 40: 209-217, 1971
36. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002 (Pubitemid 35286260)
37. Kalantar-Zadeh K, Brennan ML, Hazen SL: Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 48: 59-68, 2006
38. Hazen SL: Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 24: 1143-1146, 2004
39. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P: Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 24: 1309-1314, 2004 (Pubitemid 38880026)
40. Abu-Soud HM, Hazen SL: Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275: 5425-5430, 2000 (Pubitemid 30115174)
41. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL: Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105: 1095-1108, 2000 (Pubitemid 30217694)
42. Rudolph TK, Wipper S, Reiter B, Rudolph V, Coym A, Detter C, Lau D, Klinke A, Friedrichs K, Rau T, Pekarova M, Russ D, Knöll K, Kolk M, Schroeder B, Wegscheider K, Andresen H, Schwedhelm E, Boeger R, Ehmke H, Baldus S: Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J 33: 1625-1634, 2012
43. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110: 1134-1139, 2004 (Pubitemid 39319014)
44. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541, 2004 (Pubitemid 39572103)
45. Hasuike Y, Nakanishi T, Moriguchi R, Otaki Y, Nanami M, Hama Y, Naka M, Miyagawa K, Izumi M, Takamitsu Y: Accumulation of cyanide and thiocyanate in haemodialysis patients. Nephrol Dial Transplant 19: 1474-1479, 2004 (Pubitemid 38786741)
46. Turunen S, Koivula MK, Risteli L, Risteli J: Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum 62: 3345-3352, 2010
47. Brennan ML, Wu W, Fu X, Shen Z, Song W, Frost H, Vadseth C, Narine L, Lenkiewicz E, Borchers MT, Lusis AJ, Lee JJ, Lee NA, Abu-Soud HM, Ischiropoulos H, Hazen SL: A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 277: 17415-17427, 2002 (Pubitemid 34967541)
48. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277: 46116-46122, 2002 (Pubitemid 35417600)
49. Colman S, Bross R, Benner D, Chow J, Braglia A, Arzaghi J, Dennis J, Martinez L, Baldo DB, Agarwal V, Trundnowski T, Zitterkoph J, Martinez B, Khawar OS, Kalantar-Zadeh K: The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: Overview of the NIED study and the role of dietitians. J Ren Nutr 15: 231-243, 2005
50. Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, Kovesdy CP, Kopple JD, Kalantar-Zadeh K: Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: A 5-year prospective cohort study. Am J Kidney Dis 53: 298-309, 2009
51. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108: 609-613, 2000 (Pubitemid 30336599)
52. Fried L, Bernardini J, Piraino B: Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 37: 337-342, 2001 (Pubitemid 32116026)
53. Erbaǧci AB, Tarakçioǧlu M, Aksoy M, Kocabaş R, Nacak M, Aynacioǧlu AS, Sivrikoz C: Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol 57: 197-204, 2002 (Pubitemid 34625365)
54. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002 (Pubitemid 35315836)
55. Kalantar-Zadeh K, Block G, Kelly MP, Schroepfer C, Rodriguez RA, Humphreys MH: Near infra-red interactance for longitudinal assessment of nutrition in dialysis patients. J Ren Nutr 11: 23-31, 2001 (Pubitemid 33602025)
56. Kalantar-Zadeh K, Dunne E, Nixon K, Kahn K, Lee GH, Kleiner M, Luft FC: Near infra-red interactance for nutritional assessment of dialysis patients. Nephrol Dial Transplant 14: 169-175, 1999 (Pubitemid 29041889)
57. Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K: Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol 1: 70-78, 2006
58. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172, 2008 (Pubitemid 351193639)